MPVLR Glasgow预后评分与急性冠脉综合征患者PCI一年内预后的关系

doi:10.3969/j.issn.1006-6233.2023.04.026

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1251 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨平均血小板体积与淋巴细胞比值(mean platelet volume to lymphocyte ratio,MPVLR)、格拉斯哥预后评分(Glasgow prognosis score,Glasgow)与急性冠脉综合征患者经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后预后的关系。方法: 选取2019年1月至2021年7月在我院治疗的急性冠脉综合征患者98例,根据术后1年是否发生心源性或全因死亡、急性心力衰竭等主要不良心血管事件(major adverse cardiovascular events ,MACE)分为预后不良组和预后良好组,分别为30例和68例,观察比较预后不良和良好组患者GRACE评分、Glasgow评分、MPVLR等临床资料等差异。结果: 预后不良组患者入院GRACE评分为(145.50±19.29)分,明显高于预后良好组患者(P<0.05);预后不良组患者Glasgow评分1~2分比例为80.00%,明显高于预后良好组患者(P<0.05);预后不良组患者MPVLR和肌钙蛋白T(cardiac troponin T ,cTnT)峰值分别为(6.90±1.01)和(6.69±1.32)ng/mL,明显高于预后良好组患者(P<0.05);预后不良组患者左室射血分数(left ventricular ejection fraction,LVEF)为(46.60±7.82)%,明显低于预后良好组患者(P<0.05);Logistic回归分析显示:Glasgow评分、MPVLR及LVEF是急性冠脉综合征患者PCI术后预后不良的影响因素(P<0.05)。结论: 入院时MPVLR、Glasgow评分与急性冠脉综合征患者PCI术后预后不良有关,值得进一步研究。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张同昌
	李海山

关键词 ：急性冠脉综合征, 平均血小板体积与淋巴细胞比值, 格拉斯哥预后评分, 经皮冠状动脉介入治疗, 预后

Abstract：Objective: To explore the correlation of the mean platelet volume to lymphocyte ratio (MPVLR), Glasgow prognosis score (Glasgow) and the prognosis of patients with acute coronary syndrome after percutaneous coronary intervention (PCI). Methods: A total of 98 patients with acute coronary syndrome treated in our hospital from January 2019 to July 2021 were selected, according to whether major adverse cardiovascular events (MACE) such as cardiac or all-cause death and acute heart failure occurred one year after operation, they were divided into poor prognosis group and good prognosis group, with 30 cases and 68 cases respectively. The differences of clinical data such as GRACE score, Glasgow score and MPVLR of patients with poor prognosis and those with good prognosis were observed and compared. Results: The admission GRACE score of patients with poor prognosis was (145.50 ± 19.29), which was significantly higher than that of patients with good prognosis (P<0.05). The proportion of Glasgow score 1-2 in patients with poor prognosis was 80.00%, which was significantly higher than that in patients with good prognosis (P<0.05). The peak values of MPVLR and cardiac troponin T (cTnT) in patients with poor prognosis were (6.90 ± 1.01) and (6.69 ± 1.32) ng / ml, respectively, which were significantly higher than those in patients with good prognosis (P<0.05). The left ventricular ejection fraction (LVEF) of patients with poor prognosis was (46.60 ± 7.82)%, which was significantly lower than that of patients with good prognosis (P<0.05); Logistic regression analysis showed that Glasgow score, MPVLR and LVEF were the influencing factors of poor prognosis after PCI in patients with acute coronary syndrome (P<0.05). Conclusion: MPVLR and Glasgow scores at admission are related to poor prognosis of patients with acute coronary syndrome after PCI, which is worthy of further study.

Key words： Acute coronary syndrome Mean platelet volume to lymphocyte ratio Glasgow prognostic score Percutaneous coronary intervention Prognosis

基金资助:安徽省卫生健康委科研项目,(编号:AHWJ2021a025)

通讯作者: 李海山

引用本文:

张同昌, 李海山. MPVLR Glasgow预后评分与急性冠脉综合征患者PCI一年内预后的关系[J]. 河北医学, 2023, 29(4): 658-663.
ZHANG Tongchang, LI Haishan. Association of MPVLR Glasgow Prognostic Score and Prognosis within One Year of PCI in Patients with Acute Coronary Syndrome. HeBei Med, 2023, 29(4): 658-663.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.04.026 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I4/658

[1] Piroli F,Leone A M,Calcagno S.The role of chronic obstructive pulmonary disease in acute coronary syndrome patients:a critical risk factor for lipid plaque burden[J].Minerva Cardioangiologica,2021,69(6):735-737.
[2] Hayajneh A A,Rababa M,Al-Rawashedeh S.Time to seek care and hospital length of stay among older adults with acute coronary syndrome during the COVID-19 pandemic[J].Clinical Nursing Research,2022,31(3):364-375.
[3] Elbehairy M M,Abdelnasser H Y,Hanafi R S,et al.An intronic DHCR7 genetic polymorphism associates with vitamin D serum level and incidence of acute coronary syndrome[J].Steroids,2021,169(5):108825.
[4] Toth P P,Schwartz G G,Nicholls S J,et al.Reduction in the risk of MACE with apabetalone in patients with recent acute coronary syndrome and diabetes according to NAFLD fibrosis score:exploratory analysis of the BETonMACE trial[J].European Heart Journal,2021,22(11):3321.
[5] Kalantar-Zadeh K,Schwartz G G,Nicholls S J,et al.Effect of apabetalone on cardiovascular events in diabetes,CKD,and recent acute coronary syndrome:results from the BETonMACE randomized controlled trial[J].Clinical Journal of the American Society of Nephrology,2021,16(5):705-716.
[6] Zhang W,Kong Y,Wang L,et al.Prognostic value of serum calprotectin level in elderly diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention:a cohort study[J].Medicine,2020,99(33):20805.
[7] 王康鸣,吉家钗,王琦,等.高Glasgow预后评分与急性冠脉综合征患者的全因死亡率和心血管死亡率独立相关[J].内科急危重症杂志,2022,28(2):133-136.
[8] Koseoglu C,Kurmus O.Association between mean platelet volume-to-lymphocyte ratio and the presence of apical mural thrombus in post-myocardial infarction patients[J].International Journal of Cardiovascular Sciences,2020,33(33):422.
[9] Angkananard T,Inthanoo T,Sricholwattana S,et al.The predictive role of neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume-to-lymphocyte ratio (MPVLR) for cardiovascular events in adult patients with acute heart failure.[J].Hindawi Limited,2021,18(8):6889733.
[10] 中国医师协会急诊医师分会,中华医学会心血管病学分会,中华医学会检验医学分会.急性冠脉综合征急诊快速诊疗指南[J].中华危重症医学杂志(电子版),2016,9(2):73-80.
[11] Zhu K,Zheng Y S,Fang Y.Effect of trimetazidine on incidence of major adverse cardiac events in coronary artery disease patients undergoing percutaneous coronary intervention:a protocol for systematic review and meta-analysis[J].Medicine,2020,99(44):22918.
[12] 袁健瑛,程毅松,贾禹,等.基于炎症的格拉斯哥预后评分对急性ST段抬高型心肌梗死患者预后的预测价值分析[J].中国胸心血管外科临床杂志,2020,27(1):14-19.
[13] 邹洋,王慎旭.急性ST段抬高型心肌梗死患者PCI术后不同预后患者凝血功能的研究[J].川北医学院学报,2020,35(2):255-258.
[14] Chen Z,Li N,Wang J,et al.Association between mean platelet volume and major adverse cardiac events in percutaneous coronary interventions:a systematic review and meta-analysis[J].Coronary Artery Disease,2020,31(8):722-732.